ATE306903T1 - Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren - Google Patents

Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren

Info

Publication number
ATE306903T1
ATE306903T1 AT96908878T AT96908878T ATE306903T1 AT E306903 T1 ATE306903 T1 AT E306903T1 AT 96908878 T AT96908878 T AT 96908878T AT 96908878 T AT96908878 T AT 96908878T AT E306903 T1 ATE306903 T1 AT E306903T1
Authority
AT
Austria
Prior art keywords
adhesions
active oxygen
reduction
oxygen inhibitors
sod
Prior art date
Application number
AT96908878T
Other languages
English (en)
Inventor
Keith Baker
Arthur J Coury
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ATE306903T1 publication Critical patent/ATE306903T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Catalysts (AREA)
AT96908878T 1995-03-24 1996-03-20 Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren ATE306903T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41021995A 1995-03-24 1995-03-24
PCT/US1996/003813 WO1996029987A1 (en) 1995-03-24 1996-03-20 Reduction of adhesions using controlled delivery of active oxygen inhibitors

Publications (1)

Publication Number Publication Date
ATE306903T1 true ATE306903T1 (de) 2005-11-15

Family

ID=23623783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908878T ATE306903T1 (de) 1995-03-24 1996-03-20 Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren

Country Status (8)

Country Link
US (2) US5785993A (de)
EP (1) EP0814774B1 (de)
JP (1) JP3145409B2 (de)
AT (1) ATE306903T1 (de)
AU (1) AU704222B2 (de)
CA (1) CA2215317C (de)
DE (1) DE69635301T2 (de)
WO (1) WO1996029987A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE306903T1 (de) * 1995-03-24 2005-11-15 Genzyme Corp Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US6039757A (en) * 1997-03-12 2000-03-21 Cardiosynopsis, Inc. In situ formed fenestrated stent
AU6769098A (en) * 1997-03-20 1998-10-12 Focal, Inc. Biodegradable tissue retractor
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
AU1520699A (en) 1997-11-07 1999-05-31 Johns Hopkins University, The Methods for treatment of disorders of cardiac contractility
ES2297934T3 (es) * 1998-08-03 2008-05-01 Ronald E. Wheeler Formula prostatica.
US6525100B1 (en) 1998-08-03 2003-02-25 W. Jerry Easterling Composition and method for treating peyronie's disease and related fibrotic tissue disorders
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6627663B2 (en) 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US20080114092A1 (en) * 1998-12-04 2008-05-15 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
JP2003528148A (ja) * 2000-03-28 2003-09-24 デロレンゾ、ロバート・ジェイ 損傷に際して神経細胞中に形成される新規カルシウム損傷電流の阻害は神経細胞死を抑制する
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
KR20050000416A (ko) * 2002-04-30 2005-01-03 핏 바이오테크 오와이제이 피엘씨 의료 장치
CN100490900C (zh) * 2002-08-20 2009-05-27 精密技术公司 骨生长诱导材料的携带和输送用组合物以及生产和应用该组合物的方法
WO2004039415A2 (en) 2002-10-28 2004-05-13 Northgate Technologies Inc. Dual-capacity insufflator tube
US7654975B2 (en) 2003-04-24 2010-02-02 Northgate Technologies, Inc. Mixed-gas insufflation system
AU2004279319B2 (en) * 2003-09-23 2010-11-04 Abyrx, Inc Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
ES2336796T3 (es) 2003-10-07 2010-04-16 Northgate Technologies Incorporated Sistema para suministrar una sustancia a una cavitacion corporal.
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7332179B2 (en) * 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US20050244480A1 (en) * 2004-04-30 2005-11-03 Kimberly-Clark Worldwide, Inc. Pre-wipes for improving anal cleansing
US7642395B2 (en) * 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US20060140899A1 (en) * 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. Skin cleansing system comprising an anti-adherent formulation and a cationic compound
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
EP1906992A1 (de) * 2005-06-28 2008-04-09 Life Science Investments Limited Verwendung eines gemisches von superoxid-dismutase und catalase zur behandlung von entzündlichen hauterkrankungen
EP1962870A4 (de) * 2005-11-14 2010-08-11 Univ Delaware Technology Corp Neuartige hydrogele und ihre verwendung
US7706852B2 (en) 2006-01-30 2010-04-27 Nellcor Puritan Bennett Llc System and method for detection of unstable oxygen saturation
CA2660050A1 (en) 2006-08-04 2008-02-07 Northgate Technologies Inc. In-dwelling port for access into a body
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
CN106913902A (zh) 2009-11-09 2017-07-04 聚光灯技术合伙有限责任公司 多糖基水凝胶
CN102695501A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 碎裂水凝胶
US9555054B2 (en) 2012-11-21 2017-01-31 University Of Louisville Research Foundation, Inc. Compositions and methods for reducing oxidative damage
US9572595B1 (en) 2014-03-05 2017-02-21 Northgate Technologies Inc. In-dwelling port for access into a body
EP3256136A4 (de) 2015-02-09 2018-11-21 University Of Louisville Research Foundation, Inc. Ophthalmische zusammensetzungen und verfahren zur reduzierung von oxidativen schäden einer augenlinse
US10590257B2 (en) 2016-09-26 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Biomimetic, moldable, self-assembled cellulose silica-based trimeric hydrogels and their use as viscosity modifying carriers in industrial applications
CN106468668B (zh) * 2016-09-28 2019-03-12 北京凯视佳光电设备有限公司 工业相机圆柱检测方法
US11975123B2 (en) 2018-04-02 2024-05-07 The Board Of Trustees Of The Leland Stanford Junior University Adhesion prevention with shear-thinning polymeric hydrogels
US12599706B2 (en) 2017-04-03 2026-04-14 The Board Of Trustees Of The Leland Stanford Junior University Adhesion prevention with shear-thinning polymeric hydrogels
US11969526B2 (en) 2017-04-03 2024-04-30 The Board Of Trustees Of The Leland Stanford Junior University Adhesion prevention with shear-thinning polymeric hydrogels
US11911504B2 (en) 2018-02-02 2024-02-27 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
EP3860613B1 (de) 2018-10-01 2025-09-10 The Board of Trustees of the Leland Stanford Junior University Injizierbare hydrogele zur kontrollierten freisetzung immunmodulatorischer verbindungen

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784585A (en) * 1971-10-21 1974-01-08 American Cyanamid Co Water-degradable resins containing recurring,contiguous,polymerized glycolide units and process for preparing same
US4371519A (en) * 1972-06-05 1983-02-01 Hettinger Jr William P Methods of treating cellular tissue
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4563349A (en) * 1980-07-30 1986-01-07 Takeda Chemical Industries, Ltd. Superoxide dismutase, its immobilized form, and their production and use
EP0092918B1 (de) * 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Mittel mit verzögerter Freigabe
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
JPS6014861A (ja) * 1983-07-05 1985-01-25 株式会社日本メデイカル・サプライ 癒着防止材
ATE155527T1 (de) * 1983-10-03 1997-08-15 Chiron Corp Superoxiddismutase und deren expression in mikroorganismen
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4873292A (en) * 1984-12-28 1989-10-10 Research Development Corporation Of Japan Antithrombogenic synthetic polymer and process for its preparation
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
IN166447B (de) * 1985-11-27 1990-05-12 Ethicon Inc
US4889722A (en) * 1985-12-16 1989-12-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US4806621A (en) * 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5547988B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
US5260204A (en) * 1987-03-14 1993-11-09 Boehringer Ingelheim International Gmbh Human manganese superoxide dismutase (hMn-SOD)
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
EP0292964B1 (de) * 1987-05-28 1995-04-05 Hiroshi Maeda Superoxid-Dismutase-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
HU209955B (en) * 1987-07-01 1994-12-28 Genentech Inc Process for producing pharmaceutical compositions containing tissue- -plasminogen-activator of poor solubility for inhibiting production and regeneration of deformities
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4804691A (en) * 1987-08-28 1989-02-14 Richards Medical Company Method for making a biodegradable adhesive for soft living tissue
US5364622A (en) * 1987-12-04 1994-11-15 Dr. Karl Thomae Gmbh Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
US4888413A (en) * 1988-01-11 1989-12-19 Domb Abraham J Poly(propylene glycol fumarate) compositions for biomedical applications
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
CA2004740A1 (en) * 1988-12-07 1990-06-07 Cary Linsky Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process
US5108755A (en) * 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US4994277A (en) * 1989-10-31 1991-02-19 Pfizer Hospital Products Group, Inc. Use of xanthan gum for preventing adhesions
US5175235A (en) * 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
EP0589871B1 (de) * 1990-02-13 2000-04-26 Ethicon, Inc. Peritoneal wirksame medikamente
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5217966A (en) * 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
AU673160B2 (en) * 1992-02-28 1996-10-31 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
WO1993019660A1 (en) * 1992-04-03 1993-10-14 Baylor College Of Medicine Gene therapy using the intestine
EP0690736B1 (de) * 1993-03-23 1998-11-11 Focal, Inc. Gerät und methode für den lokalen auftrag von polymermaterial auf gewebe
ATE169483T1 (de) * 1993-04-28 1998-08-15 Focal Inc Vorrichtung, produkt und verwendung betreffend die intraluminale photothermoformgebung
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
PT705298E (pt) * 1993-12-01 2002-07-31 Bioartificial Gel Technologies Inc Hidrogel a base de albumina
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
IL109539A0 (en) * 1994-05-03 1994-08-26 Yissum Res Dev Co Substained-release pharmaceutical system for the delivery of antioxidants
US5478837A (en) 1994-06-07 1995-12-26 University Of Southern California Use of quinacrine in preventing adhesion formation
US5562594A (en) * 1994-06-10 1996-10-08 Duke University Shielded mini-applicator system for radioactive source treatment of cancer of the uterine cervix
ATE306903T1 (de) * 1995-03-24 2005-11-15 Genzyme Corp Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US5527864A (en) * 1995-08-08 1996-06-18 Suggs; Laura J. Poly(propylene fumarate-co-ethylene oxide)

Also Published As

Publication number Publication date
US5785993A (en) 1998-07-28
JPH10508872A (ja) 1998-09-02
CA2215317C (en) 2002-07-23
JP3145409B2 (ja) 2001-03-12
DE69635301T2 (de) 2006-07-20
EP0814774A1 (de) 1998-01-07
DE69635301D1 (de) 2006-03-02
WO1996029987A1 (en) 1996-10-03
US20010046503A1 (en) 2001-11-29
CA2215317A1 (en) 1996-10-03
AU5257596A (en) 1996-10-16
AU704222B2 (en) 1999-04-15
EP0814774B1 (de) 2005-10-19
US6780427B2 (en) 2004-08-24

Similar Documents

Publication Publication Date Title
ATE306903T1 (de) Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
DE69425509D1 (de) Lokale verabreichung von fibrinolyse verstärkendemitteln
CA2187353A1 (en) Liquid delivery compositions
CA2177772A1 (en) Pharmaceutical compositions containing irbesartan
GB9212511D0 (en) Pharmaceutical compositions
PT1028707E (pt) Formulacoes oftalmicas de libertacao controlada contendo medicamentos soluveis em agua
EP1516615A3 (de) Feste Verabreichungssysteme zur gesteuerten Freisetzung von darin eingebauten Molekülen sowie Verfahren zu deren Herstellung
DE60023138D1 (de) Verwendung eines biologisch abbaubaren Polymers
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
DK0689426T3 (da) Terapeutisk middel til behandling af melanomer
TR199700943T1 (xx) Organik bile�iklerde veya bu bile�iklere ili�kin geli�meler.
EP0598337A3 (de) Arznei Zusammensetzungen, die ein Arzneimittel, ein quervernetztes Polymer, ein Öl, und ein grenzflächenaktives Mittel enthalten.
ATE167800T1 (de) Polymeres arzneimittelabgabesystem
DE50004443D1 (de) Wirkstoffhaltige komposition sowie deren herstellung und verwendung
DE69619052D1 (de) Feste, wasserfreie, pharmazeutische Zubereitungen für vaginale Verwendung
CA2231176A1 (en) Long active composition for rectal administration
AU8025998A (en) Biologically active materials
BR9810285A (pt) Solução, composição farmacêutica, e, cápsula de gelatina.
CO4960657A1 (es) Composicion farmaceutica
DE59703910D1 (de) Verwendung von asparaginsäure-haltigen polymeren in mit bioziden versetzten kühlkreisläufen
ES2165970T3 (es) Forma farmaceutica solida con principio activo distribuido en un material polimerico.
ATE235909T1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties